| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +750K | 70.7% | $2.75 | +$2.06M |
| Sells | 2 | -312K | 29.3% | $3.09 | -$964K |
| Net | -1 | +438K | 41.3% | +$1.1M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| R.A. Session II | 10%+ Owner | $14.7M | Jul 12, 2023 | ||
| Audentes Therapeutics, Inc. | 10%+ Owner | $11.8M | Oct 21, 2022 | ||
| Sean P. Nolan | Chief Executive Officer, Director | $8.13M | Jan 2, 2025 | ||
| Paul B. Manning | 10%+ Owner | $7.81M | +$2.06M | +35.9% | May 30, 2025 |
| John A. Stalfort III | Director | $6.12M | Jun 2, 2025 | ||
| Kamran Alam | Chief Financial Officer | $3.38M | -$155K | -4.39% | Aug 21, 2025 |
| Sukumar Nagendran | President and Head of R&D, Director | $3.32M | -$809K | -19.6% | Sep 10, 2025 |
| Suyash Prasad | CMO and Head of R&D | $865K | Jul 5, 2022 | ||
| Phillip B. Donenberg | Director | $660K | Jun 2, 2025 | ||
| Alison S. Long | Director | $318K | Jun 2, 2025 | ||
| Laura Sepp-Lorenzino | Director | $318K | Jun 2, 2025 | ||
| Kathleen Reape | Director | Jun 22, 2023 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|